Drug Profile
Buprenorphine - Relmada Therapeutics
Alternative Names: Buprenorphine ER - Relmada Therapeutics; Buprenorphine extended release - Relmada Therapeutics; BuTab ER; REL-1028; TQ-1028Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator TheraQuest Biosciences LLC
- Developer Relmada Therapeutics
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Opioid-related disorders; Pain
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Opioid-related-disorders(In volunteers) in Canada (PO, Controlled release)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Pain(In volunteers) in Canada (PO, Controlled release)
- 30 Jan 2019 Buprenorphine is still in phase I trials for Pain and Opioid abuse in Canada (Relmada pipeline, January 2019)